The first sphingosine 1-phosphate lyase inhibitors against multiple sclerosis: A successful drug discovery tale

Journal of Medicinal Chemistry

Volumn 57, Issue 12, 2014, Pages 5072-5073

  Cosconati, Sandro ^a   Novellino, Ettore ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; LYASE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE LYASE; SPHINGOSINE 1 PHOSPHATE LYASE INHIBITOR; UNCLASSIFIED DRUG;

DRUG POTENCY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; MALE; MULTIPLE SCLEROSIS; NONHUMAN; RAT; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ALDEHYDE-LYASES; ANIMALS; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; PHTHALAZINES; PYRIDINES;

EID: 84903519268     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500845y     Document Type: Review

References (9)

1. Compston, A.; Coles, A. Multiple sclerosis Lancet 2002, 359, 1221-1231
2. Jacobs, D.; Cookfair, L.; Rudick, A.; Herndon, M.; Richert, R.; Salazar, M.; Fischer, S.; Goodkin, E.; Granger, V.; Simon, H.; Alam, J.; Bartoszak, M.; Bourdette, N.; Braiman, J.; Brownscheidle, M.; Coats, E.; Cohan, L.; Dougherty, S.; Kinkel, P.; Mass, K.; Munschauer, E.; Priore, L.; Pullicino, M.; Scherokman, J.; Whitham, H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis Ann. Neurol. 1996, 39, 285-294
3. Johnson, P.; Brooks, R.; Cohen, A.; Ford, C.; Goldstein, J.; Lisak, P.; Myers, W.; Panitch, S.; Rose, W.; Schiffer, B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial Neurology 1995, 45, 1268-1276
4. Goodin, S.; Frohman, M.; Garmany, P.; Halper, J.; Likosky, H.; Lublin, D.; Silberberg, H.; Stuart, H.; van den Noort, S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines Neurology 2002, 58, 169-178
5. Galetta, S. L.; Markowitz, C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles CNS Drugs 2005, 19, 239-252
6. Matloubian, M.; Lo, C. G.; Cinamon, G.; Lesneski, M. J.; Xu, Y.; Brinkmann, V.; Allende, M. L.; Proia, R. L.; Cyster, J. G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 Nature 2004, 427, 355-360
7. Chiba, K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors Pharmacol. Ther. 2005, 108, 308-319
8. Schwab, S. R.; Pereira, J. P.; Matloubian, M.; Xu, Y.; Huang, Y.; Cyster, J. G. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients Science 2005, 309, 1735-1739
9. Weiler, S.; Braendlin, N.; Beerli, C.; Bergsdorf, C.; Schubart, A.; Srinivas, H.; Oberhauser, B.; Billich, A. Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis J. Med. Chem. 2014, 10.1021/jm500338n.